From the IASLC Early Detection and Screening Committee Terminology Issues in Screening and Early Detection of Lung Cancer - IASLC Early Detection and Screening Committee Expert Group Recommendations.


Journal

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
ISSN: 1556-1380
Titre abrégé: J Thorac Oncol
Pays: United States
ID NLM: 101274235

Informations de publication

Date de publication:
02 Aug 2024
Historique:
received: 30 04 2024
revised: 23 07 2024
accepted: 26 07 2024
medline: 5 8 2024
pubmed: 5 8 2024
entrez: 4 8 2024
Statut: aheadofprint

Résumé

To facilitate global implementation of lung cancer (LC) screening and early detection in a quality assured and consistent manner, common terminology is needed. Researchers and clinicians within different specialties may use the same terms but with different meanings, or different terms for the same intended meanings. The Diagnostics Working Group of the International Association for the Study of Lung Cancer Early Detection and Screening Committee has analyzed and discussed relevant terms used on a regular basis and suggests recommendations for consensus definitions of terminology applicable in this setting. We explored how to reach consensus to define relevant and unambiguous terminology for use by health care providers, researchers, patients, screening participants and family. Terms and definitions for epidemiological and health-economical purposes included: Standardized incidence and mortality rates, LC specific survival, long-term survival and cure rates, and overdiagnosis, overtreatment, undertreatment. Terms and definitions for defining screening findings included: Positive, false positive, negative, false negative and indeterminate findings and additional and incidental findings. Terms and definitions for describing parameters in screening programmes included: Opportunistic vs programmatic screening, screening rounds, interval/interim diagnoses, invasive and minimally invasive procedures. Terms and definitions for shared decision making included: LC screening - possible harms and risks and LC risk and modifiers prior and posterior to a measure. A common set of terminology with standard definitions is recommended for describing clinical LC screening programmes, the discussion about effectiveness and outcomes, or the clinical setting. The use of the terms should be clearly defined and explained.

Identifiants

pubmed: 39098452
pii: S1556-0864(24)00747-0
doi: 10.1016/j.jtho.2024.07.022
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Investigateurs

Dawei Yang (D)
Javier Zulueta (J)
Lucia Viola (L)
Anant Mohan (A)
Milena Cavic (M)
Haval Balata (H)
Ella Kazerooni (E)
Ricardo Sales Dos Santos (R)
Anna Kerpel-Fronius (A)
Claudia Henschke (C)
Luigi Ventura (L)
Long Jiang (L)
Anne Fraser (A)
Coenraad Fn Koegelenberg (CF)
Martin Tammemägi (M)
Stephen Lam (S)
Rudolf Huber (R)

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Auteurs

Rudolf M Huber (RM)

Division of Respiratory Medicine and Thoracic Oncology, Department of Medicine V, Ludwig-Maximilian-University of Munich, Thoracic Oncology Centre Munich, German Centre for Lung Research (DZL CPC-M), Munich, Germany.

Milena Cavic (M)

Department of Experimental Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia.

Haval Balata (H)

Manchester University NHS Foundation Trust, Manchester, UK.

Andrea Borondy Kitts (AB)

Rescue Lung Society, Prosumer Health, US.

John K Field (JK)

Roy Castle Lung Cancer Research Programme, The University of Liverpool, Department of Molecular and Clinical Cancer Medicine, Liverpool, UK.

Claudia Henschke (C)

Department of Radiology, Phoenix Veterans Affairs Health Care System, Phoenix, Arizona; Department of Radiology, Icahn School of Medicine Mount Sinai, New York, New York, US.

Ella A Kazerooni (EA)

Division of Cardiothoracic Radiology, Department of Radiology, University of Michigan Medical School/Michigan Medicine, Ann Arbor, Michigan, USA; Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, University of Michigan Medical, School/Michigan Medicine, Ann Arbor, Michigan, USA.

Anna Kerpel-Fronius (A)

Department of Radiology, National Korányi Institute for Pulmonology, Budapest, Hungary.

Robert A Smith (RA)

Center for Early Cancer Detection Science, American Cancer Society, US.

Emanuela Taioli (E)

Institute for translational epidemiology, Icahn School of Medicine Mount Sinai, New York/NY/USA.

Luigi Ventura (L)

Barts Thorax Centre, St Bartholomew's Hospital, London, UK.

Stephen Lam (S)

Department of Integrative Oncology, BC Cancer and Department of Medicine, University of British Columbia, Vancouver, Canada.

David Yankelevitz (D)

Department of Radiology, Icahn School of Medicine Mount Sinai, New York, New York, US.

Martin Tammemägi (M)

Cancer Control & Evidence Integration, Ontario Health (Cancer Care Ontario), Toronto, Ontario, Canada; Department of Health Sciences, Brock University, St. Catharines, Ontario, Canada.

Classifications MeSH